Spatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection by Su Jin et al.
Jin et al. Retrovirology  (2016) 13:12 
DOI 10.1186/s12977-016-0243-3
RESEARCH
Spatiotemporal hierarchy in antibody 
recognition against transmitted HIV-1 envelope 
glycoprotein during natural infection
Su Jin1, Yangtao Ji2, Qian Wang1, Hua Wang1, Xuanling Shi1, Xiaoxu Han2, Tongqing Zhou3, Hong Shang2* 
and Linqi Zhang1*
Abstract 
Background: Majority of HIV-1 infection is established by one transmitted/founder virus and understanding how the 
neutralizing antibodies develop against this virus is critical for our rational design an HIV-1 vaccine.
Results: We report here antibody profiling of sequential plasma samples against transmitted/founder HIV-1 envelope 
glycoprotein in an epidemiologically linked transmission pair using our previously reported antigen library approach. 
We have decomposed the antibody recognition into three major subdomains on the envelope and showed their 
development in vivo followed a spatiotemporal hierarchy: starting with the ectodomain of gp41 at membrane 
proximal region, then the V3C3V4 and the V1V2 of gp120 at the membrane distal region. While antibodies to these 
subdomains appeared to undergo avidity maturation, the early anti-gp41 antibodies failed to translate into detect-
able autologous neutralization. Instead, it was the much delayed anti-V3C3V4 and anti-V1V2 antibodies constituted 
the major neutralizing activities.
Conclusions: Our results indicate that the initial antibody response was severely misguided by the transmitted/
founder virus and future vaccine design would need to avoid the ectodomain of gp41 and focus on the neutralizing 
targets in the V3C3V4 and V1V2 subdomains of gp120.
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Background
Neutralizing antibodies are the major component of 
protective immunity against viral infection in humans. 
Polyclonal by nature, they exert their function by target-
ing the crucial antigenic domains on the viral envelop 
glycoprotein. Identifying the neutralizing antibodies 
and their recognized antigenic domains have therefore 
become the first crucial step for better understanding of 
the protective antibody response and the rational design 
of immunogens capable of eliciting the neutralizing anti-
bodies [1–5]. In human immunodeficiency virus type I 
(HIV-1) infection, viral glycoprotein gp160 that mediates 
infection of CD4+ T lymphocytes is the sole target for 
neutralizing antibodies. The gp160 is composed of exte-
rior, receptor-binding gp120 and the fusion-mediating, 
transmembrane gp41 subunits. The unique feature of 
gp160 is its extensive glycosylation and genetic diversity 
manifested by rapid generation and high turnover of viral 
variants during infection [6]. Sequence and structural 
analysis has revealed the glycosylation and mutations are 
largely distributed in the hypervarible regions V1–V5 on 
the exterior surface of gp160 and function to protect the 
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Majority of HIV-1 infection is established by one trans-
mitted/founder virus with distinct genetic and pheno-
typic properties compared to those in the later stages of 
infection [9–12]. The development of neutralizing anti-
bodies against this virus, however, follows an unusual 
pathway of inefficiency [2, 4, 13–18]. Most of the anti-
bodies generated during the first few weeks lack neu-
tralizing activities but reactive to gp41 as well as some 
non-HIV-1 antigens [19–21]. Only after a few months 
into the infection, autologous neutralizing antibod-
ies become detectable, largely directed to gp120 and 
invariably strain-specific [4, 13, 14, 22]. Cross-reactive 
and broadly neutralizing antibodies (bnAbs) capable of 
neutralizing heterologous viruses across many genetic 
subtypes can only be generated after years into the infec-
tion and most notably in individuals who remain healthy 
despite prolonged period of infection [1–5, 15, 23]. Isola-
tion and characterization of bnAbs from these individu-
als have identified five major targets on the gp160. These 
include the CD4-binding site (CD4bs), the glycan-asso-
ciated V1V2 and V3/C3 subdomains of gp120, the mem-
brane proximal external regions (MPER) of gp41, and the 
interface between gp120 and gp41 [1–5, 15]. But how 
exactly the autologous and bnAbs are generated during 
the course of HIV-1 infection remain largely unknown. 
Several elegant studies highlighted the critical role of 
interplay between viral evolution and antibody develop-
ment. At the monoclonal levels, germline ancestors for 
neutralizing antibodies require stimulation by evolv-
ing or incoming viral variants during infection [24–29]. 
Different B cell lineages within the same individuals also 
appeared to work in concert to drive the development 
of neutralizing antibodies [25]. At the polyclonal levels, 
however, dissecting the mechanism underlying the devel-
opment of neutralizing antibodies is much more complex 
as polyclonal antibodies function through a dynamic and 
complex mixture of monoclonal antibodies with diverse 
targets on the gp160. Studies based on short peptides, 
chimeric and epitope-specific mutant viruses have iden-
tified a few subdomains of gp120 are the major targets 
for neutralizing activities in polyclonal sera [30–33]. 
However, the detailed understanding on the scope, spe-
cificities and dynamic features of polyclonal antibody 
recognition against the transmitted/founder virus remain 
elusive.
Here, we report antibody profiling of sequential plasma 
samples against transmitted/founder HIV-1 envelope 
glycoprotein in an epidemiologically linked transmis-
sion pair. Using our previously reported approach based 
on combinatorial antigen library displayed on the surface 
of the yeast Saccharomyces cerevisiae, we were able to 
delineate polyclonal antibody recognition in both quali-
tative and quantitative terms [34]. Through sequential 
analysis of plasma-reactive antigenic sequences over the 
first 2 years of infection, we decomposed the polyclonal 
antibody recognition into three major subdomains and 
showed their development in  vivo followed spatiotem-
poral hierarchy: starting at the ectodomain of gp41, then 
at the V3C3V4 and V1V2 of gp120. While antibodies to 
all three subdomains appeared to undergo avidity matu-
ration, the early anti-gp41 antibodies demonstrated no 
detectable autologous neutralization and only those 
delayed anti-V3C3V4 and anti-V1V2 antibodies con-
stituted the major neutralizing activities. Our results 
indicate that the initial antibody response was severely 
misguided by the transmitted/founder virus and future 
vaccine design would need to avoid the ectodomain of 
gp41 and focus on the neutralizing targets in the V3C3V4 
and V1V2 subdomains of gp120.
Results
Construction and validation of combinatorial antigen 
library from the transmitted HIV‑1 envelopes
To characterize dynamic changes in antibody recog-
nition during natural infection, we first constructed 
combinatorial HIV-1 envelope antigen library based 
on the transmitted/founder viruses from an epidemio-
logically linked transmission pair P08 and P11. P08 and 
P11 were identified through a Chinese acute infection 
cohort for men who have sex with men (MSM) that has 
been following several thousands of high risk individu-
als over the last decade. Epidemiologic and clinic docu-
mentation indicated that P08 infected P11 during acute 
infection. The full-length envelope sequences of the trans-
mitted/founder viruses from P08 (P08-gp160) and P11 
(P11-gp160) shared 99.9  % homology and phylogeneti-
cally grouped with those from the circulating recombi-
nant form 01_AE (CRF01_AE) (Fig. 1). The pseudoviruses 
bearing the P08-gp160 and P11-gp160 were able to infect 
the CCR5+CD4+TZM-bl cell line and demonstrated vari-
able sensitivity to a number of well characterized bnAbs 
targeted to the vulnerable sites on the envelope (Table 1). 
The protocol for constructing and validating the combina-
torial antigen library has been illustrated in greater details 
previously [34, 35]. The displayed antigenic fragments 
were centered around 30–200 residues in length (~100–
600 bases) and confirmed to include both linear and con-
formational epitopes. In this study, eight bnAbs (PG9, 
12A12, VRCPG-04, 3BNC60, 3BNC117, 10E8, 4E10, and 
2F5) recognizing either conformational or linear epitopes 
on HIV-1 envelope, were able to select the combinatorial 
antigen library built with P08-gp160 or P11-gp160 (Fig. 2). 
Though variable in length, the selected antigenic frag-
ments were clustered together in three distinct regions 
along the P08-gp160 and P11-gp160 sequences (Fig.  2a, 
c). The first cluster, selected by PG9, encompassed the 
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V1V2 region of gp120; the second, selected by the CD4bs 
antibodies 12A12, VRCPG04, 3BNC60, 3BNC117, largely 
spanned the V3, V4, and V5 regions of gp120; and the 
third, selected by 10E8, 4E10, and 2F5, covered the MPER 
region of gp41. The average length of selected antigenic 
fragments by PG9 was 118 residues, by 12A12, VRCPG04, 
3BNC60, 3BNC117 was 234 residues, and by 10E8, 4E10, 
and 2F5 was 62 residues. Furthermore, the frequency of 
each amino acid residues among all of the selected frag-
ments was analyzed and plotted along the P08-gp160 
and P11-gp160 sequences (Fig.  2b, d). The dominant 
stretch of residues for each selected antigenic cluster was 
numerically indicated and invariably covered the epitope 
specificity previously defined for each of the correspond-
ing bnAbs [36–38]. These results confirmed that the 
selected antigenic fragments contained both linear and 
conformational epitopes that were correctly folded and 
displayed on the surface of the yeast. Furthermore, as PG9 
is a glycan-dependent antibody, the selected antigenic 
fragments must also contain appropriate glycan-moiety 
for specific recognition. The significant overlap in anti-
genic fragment sequences with known epitope specifici-
ties observed here validated and reinforced the notion 
that the combinatorial antigenic libraries built with 
P08-gp160 and P11-gp160 contained both linear and con-















Fig. 1 Unrooted neighbor-joining tree depicting the genetic relatedness of full-length envelope sequences from P08 and P11 with the controls. 
Sequences from P08 and P11 are colored in red, those previously obtained from China are in green, those provided to us by John Mascola of Vac-
cine Research Center at NIH are in blue, and those commonly used reference sequences for classifying HIV-1 subtypes and CRFs were in black. The 
branch length is drawn to scale so that the relatedness between different sequences can be readily assessed. Individual sequences are named at the 
tip of the branches and their assignment to specific subtype or CRF is also indicated
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complex polyclonal antibody recognition during HIV-1 
infection.  
Spatiotemporal hierarchy in antibody development 
against distinct subdomains of HIV‑1 envelope 
during natural infection
Next, we used six sequential plasma samples from P08 
and P11 over 2 years after infection to select the antigenic 
fragments from the combinatorial libraries of transmitted/
founder P08-gp160 and P11-gp160, respectively. A total of 
706 overlapping fragments were selected by the sequential 
plasma samples and their distribution over different time 
points and along the P08-gp160 and P11-gp160 sequences 
are shown in Fig. 3a, c. Clearly, there was an intrinsic hier-
archy in the emergence of antibody recognition against 
distinct envelope subdomains during infection. In P08, for 
instance, almost all fragments selected by plasma on day 
47 and 61 after infection were confined to the ectodomain 
Table 1 Neutralization sensitivity of  transmitted/founder 
P08 and P11 pseudoviruses to various bnAbs
ND not detectable
Antibody Epitope IC50 (µg/ml)
P08‑gp160 P11‑gp160
PG9 V1V2 0.690 1.916
PG16 V1V2 ND ND
PGT121 Glycan-V3 ND ND
PGT128 Glycan-V3 0.011 0.015
PGT135 Glycan-V3 ND ND
2G12 Glycan ND ND
b12 CD4bs ND ND
VRC01 CD4bs 8.306 6.808
Ibalizumab CD4 0.027 0.022
2F5 MPER 0.415 2.17
4E10 MPER 0.571 0.568
10E8 MPER 0.131 0.217
Fig. 2 Robustness and specificity of combinatorial library approach in the selection of linear and conformational antigenic fragments by bnAbs 
with known epitope specificity. a, c Overlapping sequences of the positive yeast clones selected by bnAbs (PG09, 12A12, VRCPG04, 3BNC60, 
3BNC117, 10E8, 4E10, and 2F5) and aligned to the original full-length P08-gp160 and P11-gp160 sequence used in the construction of combinato-
rial yeast library. Vertical dashed lines highlight the V1V2, V3V4V5, and MPER regions in which the epitopes of bnAbs are located. b, d The number of 
amino acid residues among the selected fragments along their corresponding positions in the P08 and P11 envelope glycoprotein. The dominant 
stretch of amino acid residues is numbered on the top of each graph according to HXB2 and the red vertical bars separate gp120 and gp41. The 
hypervarible regions V1–V5, interspersed conserved regions C1–C5 in gp120, immune dominant (ID), MPER and transmembrane domain (TM) in 
gp41 are also indicated
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of gp41. By day 97, however, fragments largely contain-
ing V3, C3 and V4 (V3C3V4) in gp120 became detect-
able accompanied by substantial decline in proportion of 
gp41 fragments. By day 223, while increase in V3C3V4 
and decrease in gp41 fragments continued, the V1V2 
fragments began to appear. The proportion of the V1V2 
fragment continued to increase by day 557 and 741 while 
those V3C3V4 and gp41 fragments decreased (Fig.  3a). 
Similar hierarchy in antibody emergence and recognition 
was also found in P11 despite the dominant recognition 
against gp41 fragments was prolonged and that against 
V3C3V4 and V1V2 were substantially delayed compared 
to that of P08 (Fig. 3c). Of note, the size of selected frag-
ment varied from 13 to 265 residues but mostly centered 
between 30 and 200 residues, consistent with our initial 
design of the library for containing both linear and con-
formational epitopes [34, 35].
To characterize the antibody recognition in more 
quantitative manner, the frequency of each amino acid 
residues among all of the selected fragments was ana-
lyzed and plotted along the P08-gp160 and P11-gp160 
sequences (Fig.  3b, d). Similar to the dynamic changes 
in proportion and location of selected fragments, the 
total number of amino acids recognized by the plasma, 
as reflected by the area under the curve (AUC), also 
underwent rapid turnover. In P08, for example, about 
99  % antibody recognition was directed to the ectodo-
main of gp41 on day 47 and 61 after infection (Fig. 3b). 
Sequence analysis revealed a stretch of amino acid 
residues LGLWGCSGKIICTTNVPWNSTWSNKSY 
(aa593–619) (Fig. 4) was the most frequently recognized 
which in fact corresponded to the dominant epitope pre-
viously identified and included in the diagnostic kit for 
HIV-1 infection [39]. As disease progressed to day 97, 
Fig. 3 Analysis of major antigenic subdomains on the transmitted/founder HIV-1 envelope based on the positive yeast clones selected by the 
sequential plasma samples from P08 and P11. a, c Overlapping sequences of the positive yeast clones selected by the sequential plasma samples 
and aligned to the original full-length P08-gp160 and P11-gp160 sequence used in the construction of combinatorial yeast library. Vertical dashed 
lines highlight the V1V2, V3C3V4, and the ectodomain of gp41 in which the selected fragments are predominantly located. The four red horizontal 
lines from each subdomain represent the selected clones for studying avidity maturation of plasma antibodies during infection (see Fig. 5). b, d 
Quantitative measurement of antibody recognition against distinct subdomains on transmitted/founder HIV-1 envelope during natural infection. 
Each subdomain was identified based on the frequency of amino acid residues among the selected fragments and colored coded. The locations of 
the most frequently recognized residues within V1V2, V3C3V4 and ectodomain of gp41 are indicated in parentheses according to HXB2 and high-
lighted in red, blue, and green, respectively. The percentages represent the area under the curve (AUC) of each antigenic subdomain verse the total 
AUC (shaded area). The hypervarible regions V1–V5, interspersed conserved regions C1–C5 in gp120, immune dominant (ID), MPER and transmem-
brane domain (TM) in gp41 are also indicated
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antibody recognition shifted substantially to gp120 with 
over 22 % directed to V3C3V4 and concomitant decline 
to 78 % against the ectodomain of gp41. Sequence analy-
sis identified the most frequently recognized residues in 
the V3C3V4 were SIRIGPGQMFYRTGDII (aa306–323) 
(Fig. 4), consistent with earlier findings where the tip of 
the V3 loop was the most immune dominant in gp120 
[40]. By day 223, a sizable fraction of antibody recogni-
tion began to be expanded to V1V2 (7  %) while that to 
V3C3V4 increased to 39 % and to gp41 declined to 54 %. 
V1V2 recognition continued to increase to 11 % by day 
557 and 31 % by day 741 after infection while that against 
V3C3V4 and gp41 demonstrated appreciable trend of 
decline (Fig.  3b). The most frequently recognized resi-
dues in V1V2 were SIGNITDEVKNCTFNMTTEIRG-
KLQKVYALFSTLDIVHMGGNDS (aa146–189) (Fig.  4) 
which included the epitope recognized by glycan-
dependent bnAb PG09 and those isolated from RV144 
Thai HIV-1 vaccinees and naturally infected individuals 
[24, 41]. Similar pattern of antibody recognition was also 
recapitulated in P11 despite the emergence of antibody 
recognition against V3C3V4 and V1V2 was substantially 
delayed compared to that in P08 (Fig. 3d). These results 
clearly indicate a unique spatiotemporal hierarchy in 
antibody development against distinct subdomains of 
transmitted/founder HIV-1 envelope during natural 
infection.
Avidity maturation of antibody recognition against distinct 
subdomains of HIV‑1 envelope during natural infection
As antibody recognition against the ectodomain of gp41, 
V3C3V4 and V1V2 appeared in an evolving fashion over 
the course of infection, we went further to ask whether 
such recognition was associated with avidity maturation 
in the corresponding plasma. The term of “avidity matu-
ration” is used here to define the composite binding activ-
ity of polyclonal antibodies in the plasma versus “affinity 
maturation” of a monoclonal antibody commonly used 
in the field. To this end, we measured the mean fluores-
cence intensity (MFI) and calculated association constant 
(Ka) against the ectodomain of gp41, V3C3V4 and V1V2 
for the sequential plasma samples from both P08 and 
P11. Specifically, we selected representative yeast clones 
expressing the distinct envelope subdomain (highlighted 
in red in Fig.  3a, c) and mixed with a serial threefold 
dilution of the sequential plasma samples from P08 and 
P11. After 1 h incubation at room temperature and thor-
ough washes with cold phosphate-buffered saline (PBS), 
the antibody recognition of yeast clones expressing the 
distinct cluster of envelope fragments were detected by 
FACS. The MFI was recorded, plotted and fitted using 
a nonlinear least square curve against the reciprocal 
plasma dilution (Fig.  5a). The association constant (Ka) 
was then calculated for each plasma samples and plotted 
over the study period (Fig.  5b). In both P08 and P11, a 
general trend of increase in MFI was found against the 
ectodomain of gp41, V3C3V4 and V1V2 despite of their 
differences in the temporal emergence during the course 
of infection (Fig. 5a). During the first 3 months of infec-
tion, MFI against gp41 displayed significantly higher lev-
els than that against V3C3V4 and V1V2. It was not until 
the later points when MFI against V3C3V4 and V1V2 
became detectable and substantially increased. In cases 
such as P08-V1V2 and P08-gp41, the MFI appeared to be 
saturated during later stage of infection, reflected by the 
overlapping curves for the last two or three samples. Fur-
thermore, the calculated Ka also demonstrated a trend 
of increase over the course of infection (Fig. 5b). In par-
ticular, the rise in Ka against the ectodomain of gp41 was 
more profound during the first year after infection than 
the ensuing period when the Ka became relatively stable. 
Similar trend was also identified for Ka against V3C3V4 
and V1V2 although the number of measurable Ka was 
rather limited (Fig. 5b). Taken together, these results sug-
gested that while the antibody development against the 
ectodomain of gp41, V3C3V4 and V1V2 followed a spa-
tiotemporal order, there was concurrent avidity matura-
tion against all three subdomains in the corresponding 
plasma. Such maturation process appeared to undertake 
a nonlinear process with relative faster early phase fol-
lowed by a relative stable one. Similar trend of matura-
tion process was recently reported for VRC01, a bnAb 
against CD4bs, during natural infection [28].
We also used standard ELISA assay to measure the 
dynamic changes in antibody binding against three forms 
of heterologous envelope glycoprotein; trimeric ectodo-
main of NL4-3 (subtype B) constructed based on BG505 
SOSIP.664 [42], monomeric gp120 and monomeric 
gp140 (CRF01_AE). As shown in Fig.  6, there is a clear 
trend of increase in antibody binding against all forms of 
envelope glycoprotein over the course of infection. The 
last two or three plasma samples, in particular from P08, 
(See figure on previous page.) 
Fig. 4 The most frequently recognized amino acid sequences on the envelope of P08 and P11. The sequences are aligned to the full-length 
transmitted/founder HIV-1 envelope from P08 and P11 and compared with and numbered according to HXB2. The predominantly recognized 
amino acid sequences are underlines. Those highlighted in red, blue and green boxes represent the piece of sequences transplanted into the CNE6 
backbone to generate various chimeric viruses. The signal peptide, hypervarible regions V1–V5, interspersed conserved regions C1–C5 in gp120, 
immune dominant (ID), MPER and transmembrane domain (TM) in gp41 are also indicated
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demonstrated saturation effect reflected by their overlap-
ping binding curves (Fig.  6a), consistent with relatively 
stabilized binding avidity observed above against the 
three distinct subdomains on the envelope glycoprotein.
V3C3V4 and V1V2 but not gp41 contain the major targets 
for autologous neutralization
While binding antibody displayed spatiotemporal hier-
archy and avidity maturation during infection, their 
Fig. 5 Avidity maturation of subdomain-specific antibodies during natural HIV-1 infection. a For each distinct subdomain, four representative 
yeast clones were used (see Fig. 3a, c) to measure the mean fluorescence intensity (MFI) of all sequential plasma samples from P08 and P11, and 
from which the association (Ka) and disassociation (Kd) constants were calculated using nonlinear least squares fit. b Dynamic changes in Ka of 
subdomain-specific antibodies during the first 2–2.4 years of HIV-1 infection. Ka is the reciprocal of Kd
Fig. 6 Standard ELISA assay to measure the dynamic changes in plasma antibody binding of P08 (a) and P11 (b) against three forms of envelope 
glycoprotein; trimeric ectodomain of NL4-3 (subtype B) constructed based on BG505 SOSIP.664, monomeric gp120 and monomeric gp140 (CRF01_
AE)
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contribution to overall neutralization remained unclear. 
To address this question, we generated a series of chi-
meric viruses for gp41, V3C3V4, V1V2 and gp120 
derived from P08-gp160 and P11-gp160. We chose one 
of our previously characterized full-length envelopes 
(CNE6) as the backbone as it was able to confer complete 
resistance to P08 and P11 plasma neutralization (Addi-
tional file  1: Figure S1) [43]. We reasoned that if any of 
the chimeric viruses became susceptible to P08 or P11 
plasma neutralization, the replaced region should con-
tain the targets for autologous neutralization. To this 
end, we tested neutralization sensitivity of all chimeric 
viruses, along with the parental ones, against autolo-
gous sequential plasma samples from P08 and P11. As 
shown in Fig. 7a, b, replacement of gp120 but not gp41 
in the CNE6 backbone substantially transferred the neu-
tralization sensitivity to P08 and P11 plasma, suggest-
ing a major proportion of autologous neutralization was 
mediated by anti-gp120 antibodies. In P08, autologous 
neutralization against gp120-chimeras was found to 
increase until the day 223 and then declined in the ensu-
ing period, perhaps due to the emergence and turnover 
of viral variants (Fig. 7b). Within gp120, a large fraction 
of autologous neutralization appeared to be contributed 
by anti-V3C3V4 antibodies and that by anti-V1V2 anti-
bodies only occurred at much later stage of infection. 
For example, when the V3C3V4 region from P08-gp160 
or P11-gp160 was inserted into the CNE6 backbone, the 
chimeras acquired neutralization sensitivity to P08 and 
P11 plasma to the levels that were comparable to those 
inserted with entire gp120 (Fig. 7b). Furthermore, acqui-
sition of neutralization sensitivity by the V1V2 chimera 
was much delayed till day 557 in P08 and day 877 in P11 
after the initial infection (Fig.  7b). Overall, the rise in 
neutralization sensitivity of V3C3V4 and V1V2 chimeras 
appeared to temporally coincide with increase in Ka val-
ues against the same regions measured by MFI (Fig. 7b), 
suggesting increases in neutralizing activity is likely 
due to increases in binding avidity against neutralizing 
epitopes within V3C3V4 and V1V2. Collectively, these 
P08/CNE6 chimera P08 Ka P11/CNE6 chimera P11 Ka
gp160 gp120 gp41 V3C3V4 V1V2 gp41 V3C3V4 V1V2 gp160 gp120 gp41 V3C3V4 V1V2 gp41 V3C3V4 V1V2
47 39 50 ND 67 ND 107 ND ND 36 ND ND ND ND ND 121 ND ND
61 311 224 ND 500 ND 135 ND ND 62 ND ND ND ND ND 152 ND ND
97 725 416 ND 526 ND 237 37 ND 99 ND 25 ND ND ND 189 ND ND
223 5225 469 ND 726 ND 347 103 124 304 133 197 ND 184 ND 288 42 ND
557 5757 282 ND 618 25 356 91 146 442 357 310 ND 526 ND 280 48 49 






Fig. 7 Determination of major antigenic subdomains for autologous neutralization by comparing neutralizing sensitivity of parental and 
subdomain-specific chimeras to sequential plasma samples from P08 and P11. a Percent neutralization on the y axis indicates the reduction in 
luciferase activity in the presence of plasma verse those without. b Half-maximal inhibitory dilutions (ID50) were calculated as the dilution at which 
the plasma demonstrated inhibition of 50 % infection compared with the controls. The actual Ka values for corresponding plasma samples against 
each subdomain were also included for comparative purpose. Different color intensities correspond to different ID50 and Ka values for clarity, lighter 
for lower and darker for higher. ND not detectable
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data indicated that anti-gp120 and in particular anti-
V3C3V4 and V1V2 antibodies were the major source of 
autologous neutralization. In contrast, anti-gp41 anti-
bodies, despite of its early emergence and dominance 
during infection, contributed bare minimum to the over-
all autologous neutralization.
Discussion
We report here the systematic characterization of anti-
body recognition against transmitted/founder HIV-1 
envelope glycoprotein during natural infection in an 
epidemiologically linked transmission pair infected by 
highly homologous CRF01_AE strains. Based on several 
complementary approaches to determine the specifici-
ties of binding as well as neutralizing antibodies, we were 
able to decompose the complex plasma antibody recogni-
tion into three discrete subdomains on the HIV-1 enve-
lope: ectodomain of gp41, V3C3V4 and V1V2 of gp120. 
The development of these subdomain-specific antibodies 
appeared to follow a spatiotemporal hierarchy with dis-
tinct dynamic, biochemical and neutralizing properties. 
While antibodies to all three subdomains appeared to 
undergo avidity maturation, the early and strong anti-
gp41 antibodies failed to translate into detectable autol-
ogous neutralization. Instead, it was the much delayed 
anti-V3C3V4 and anti-V1V2 antibodies constituted the 
major neutralizing activities. In particular, it reinforced 
the early discoveries in that the majority of the initial 
antibody response was severely misguided by the trans-
mitted/founder virus towards its gp41 subdomain and 
therefore missed the most critical window of oppor-
tunity to contain or clear the virus replication through 
recognizing the neutralizing epitopes in the V3C3V4 
and V1V2 subdomains [19, 20]. By the time when the 
neutralizing antibody response was indeed mounted 
in a substantial manner, it was much too late and virus 
had already established its permanent residence in the 
target cells. Such defects in mistargeting and mistiming 
have provided some explanations for the failure of human 
immune system to contain viral replication during early 
infection, and strongly recommend that future vaccine 
design would need to avoid the ectodomain of gp41 and 
focus more on those neutralizing targets in the V3C3V4 
and V1V2 subdomains of gp120.
At the current stage, we are uncertain about the under-
lying mechanisms leading to the spatiotemporal hier-
archy for antibody recognition against the three major 
envelope subdomains. The overwhelming response 
against gp41 during early infection could be due to the 
pre-existing gp41 cross-reactive memory B cells that 
acquired reactivity with autologous gp41 [19, 44, 45]. 
A recent study showing majority of gut-derived anti-
gp41 antibodies cross-reacted with commensal bacteria 
supports this hypothesis [21]. It could also be due to the 
shedding of gp120 leading to the exposure of preferred 
structures during early infection although the exact step 
and timing of such preference during viral replication are 
currently unknown. Generally speaking, gp41 exhibits 
at least three distinct conformational states during the 
viral fusion process: the prefusion, the prehairpin inter-
mediate, and the postfusion conformation. It is believed 
that the conformational differences among the three 
states are so great that each of them likely presents dis-
tinct antigenic surface to the immune system [46–48]. 
So far, only the prehairpin intermediate was found to be 
the target of bnAbs such as 2F5, 4E10 and 10E8 while the 
other two states were largely recognized by non-neutral-
izing antibodies. In particular, the non-neutralizing anti-
bodies against gp41 appeared to group in two clusters 
based on the location of their respective epitopes. Clus-
ter I antibodies recognize the immunodominant C–C 
loop of gp41 (aa590–600), and the cluster II antibodies 
react with the downstream immunodominant segment 
(aa644–663) [46–49]. But whether the two clusters of 
antibodies specifically react with prefusion and postfu-
sion conformation remain to be determined. As the anti-
body recognition found in our study subjects overlapped 
with cluster I antibodies, the conformational state against 
which they were initially generated was unlikely to be the 
prehairpin intermediate. Whatever the conformational 
state was recognized, it must be the one to be avoided in 
our vaccine design to prevent non-neutralizing epitopes 
as well as severe misguidance and mistiming found dur-
ing natural infection.
Consistent with earlier reports, the appearance of 
autologous neutralizing antibodies occurred not until 
2–3 months into the infection [4, 14, 17, 22]. The major 
proportion was clearly contributed by the anti-V3C3V4, 
rather than by the anti-V1V2 antibodies. Such contribu-
tion appeared to be persistent throughout the infection 
but with the trend of increase during the first year and 
then decrease in the ensuing period of infection, perhaps 
due to the emergence and turnover of viral variants. Fur-
thermore, anti-V3C3V4 neutralizing antibody response 
was also strain-specific as plasma samples from both P08 
and P11 failed to demonstrate cross neutralizing activi-
ties against a panel of heterologous viruses (Table  2). 
These results indicate that the variable rather than the 
conserved structures within the V3C3V4 region were 
the major targets of autologous neutralization. Clearly, 
they were unlikely to include the type of epitopes rec-
ognized by the CD4bs bnAbs as the fragments selected 
by the plasma samples only encompassed V3C3V4 and 
devoid of V5 region (Fig. 2). Through sequence analysis 
of full-length envelope genes from the sequential plasma 
samples, we found that the V3 loop remained relative 
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conserved up to the time point when decline in autolo-
gous neutralizing activity was found (Additional file  1: 
Figure S2). The downstream C3 and V4 regions, however, 
displayed considerate degree of variation including both 
point mutations as well as length polymorphism (Addi-
tional file  1: Figure S2). Whether the C3 or V4 region 
alone or in combination were the major neutralization 
target and drove the viral escape from the autologous 
neutralization requires further investigation, although a 
prior study of subtype C infected individuals suggested 
the case [22, 50]. In addition, we were puzzled by the 
belated emergence of anti-V1V2 neutralizing antibody 
compared to those in subtype B and C infected individu-
als [22, 24, 51–53]. It could be related to the viral subtype 
CRF01_AE or specific structural features of the envelope 
studied in our study subjects. Similar studies involving 
more subjects infected with different viral subtypes will 
help to address this important question. At the least, it 
was unlikely the result of structural abnormality (Addi-
tional file 1: Figure S3) or major defects in infectivity of 
chimeric viruses (Additional file  1: Figure S4). Of note, 
the most frequently recognized stretch of residues in the 
V1V2 by the autologous plasma samples overlapped with 
the epitopes recognized by glycan-dependent bnAbs and 
those isolated from RV144 Thai HIV-1 vaccinees and 
naturally infected individuals [24, 41, 53]. It is uncer-
tain whether such overlapping nature in epitopes would 
trigger further maturation of strain-specific antibodies 
to become bnAb during the later stage of infection. The 
intricate and delicate interplay between evolving viral 
variants and developing B cell lineages would ultimately 
determine such likelihood [24–26]. But nevertheless, as 
V1V2 is the major target for both strain-specific as well 
as bnAbs, it should certainly serve as one of the vulner-
able targets for future vaccine design. Lastly, it needs to 
be pointed out that from the technical point of view, the 
combinational library-based approach offers unprec-
edented advantages in probing the antibody recognition 
with qualitative and quantitative specificities. However, 
it is by no means perfect. It is expected that some of 
the conformational epitopes, in particular those formed 
through inter-molecular interaction, would be lost dur-
ing the fragmentation process for library construction. 
Some subdominant epitopes, although may be important 
for neutralizing antibodies, could also be rendered unde-
tectable. We have to bear these caveats in mind when we 
analyze and interpret the data.
Conclusion
Our study has unraveled the complex and dynamic fea-
ture of antibody development against transmitted/
founder HIV-1 envelope glycoprotein during natural 
infection. The major binding and neutralizing antigenic 
subdomains identified here will provide critical reference 
for our better understanding of the spatiotemporal fea-
ture of protective antibody response during natural infec-
tion and assist our rational design of vaccines that will 
empower the strengths while minimize the weaknesses of 
human immune recognition.
Methods
Study subjects and plasma samples
Two acutely infected individuals, P08 and P11, were 
chosen for the study. P08 was 37 and P11 38  years old 
when identified through China’s largest acute infection 
cohort for man who have sex with man (MSM) that fol-
lowed several thousands of high risk individuals over the 
last decade. P08 and P11 were epidemiologically linked 
transmission pair and P08 infected P11 during acute 
infection based on epidemiologic and clinic documenta-
tion. When enrolled on day 30 after infection for P08 and 
day 18 for P11, both individuals were negative for HIV-1 
antibody measured by enzyme-linked immunosorbent 
assay (ELISA) and indeterminate Western blot test, and 
therefore fell into Fiebig II-IV substage of acute infection 
Table 2 Neutralizing activity of P08 and P11 plasma sam-
ples against  a panel of  pseudoviruses with  distinct geno-
typic and phenotypic features from China and abroad
ND not detectable
Strain Clade Origin ID50
P08‑plasma P11‑plasma
P08-gp160 CRF01_AE China 5000 3645
P11-gp160 CRF01_AE China 2500 1193
CNE5 CRF01_AE China ND ND
CNE55 CRF01_AE China 45 ND
CNE59 CRF01_AE China 463 ND
CNE6 B′ China ND ND
CNE11 B′ China ND ND
CNE14 B′ China 156 ND
CNE15 B′C China ND ND
CNE20 CRF07_BC China ND ND
CNE30 CRF08_BC China ND ND
HxB2 B France 135 ND
JRFL B USA ND ND
SF162 B USA 45 ND
KER2018.11 A Kenya ND ND
RW020.2 A Rwanda ND ND
Bal.01 B USA ND ND
YU2.DG B USA ND ND
JR-CSF.JB B USA ND ND
ZA012.29 C South Africa ND ND
ZM106.9 C Zambia ND ND
ZM55.28a C Zambia ND ND
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[54]. P08 and P11 had baseline CD4 lymphocyte count 
of 339 and 369 per cubic millimeter (FACS Calibur, BD) 
and plasma viral load of 30,600 and 889,000 RNA copies 
per milliliter (Cobas AmpliPrep/Cobas TaqMan HIV-1 
version 5.1 Assay, Roche), respectively. Both individuals 
progressed to diseases relatively fast and by 2 years into 
the infection, the CD4 lymphocyte count dropped to 147 
for P08 and 181 for P11 per cubic millimeter and plasma 
viral load remained as high as 12,500 for P08 and 40,429 
for P11 RNA copies per milliliter. Sequential plasma 
and peripheral blood mononuclear cells (PBMCs) were 
collected over the first 2  years of infection and stored 
at −80  °C until use. Neither P08 nor P11 received any 
antiretroviral therapy during the study period. This study 
was reviewed and approved by the institutional research 
ethics committee at the No. 1 Hospital of China Medical 
University in Shenyang, Liaoning Province, China.
Full‑length envelopes, phylogenetic analysis, 
pseudoviruses and neutralization assay
The full-length envelope genes from P08 (P08-gp160) 
and P11 (P11-gp160) were obtained through PCR ampli-
fication of single HIV-1 RNA molecules directly from 
the plasma samples. The reference envelopes from sub-
type A (KER2018.11 and RW020.2), subtype B (JRFL, 
Bal.01, YU2.DG) and subtype C (ZA012.29, ZM106.9, 
ZM55.28a) were kindly provided by John Mascola 
of Vaccine Research Center at National Institute of 
Health (NIH). The representative envelopes from HIV-1 
infected individuals in China came from our previ-
ously studies including those from CRF01_AE, subtype 
B′, subtype B′C, and CRF07_BC and CRF_08BC. These 
full-length envelope sequences were aligned using the 
Clustal W program together with selected subtypes/
CRFs of geographical importance from the Genbank 
database. Phylogenetic analysis was conducted using 
the neighbor-joining method and the reliability of the 
branching orders was tested by bootstrap analysis of 
1000 replicates [55].
These envelope clones were also used to generate pseu-
doviruses by co-transfection with backbone construct 
pNL43R-E-luciferase into the 293 cells. Forty-eight hours 
later, the culture supernatant containing the pseudovi-
ruses was collected and tested for luciferase activity to 
standardize viral input in the subsequent neutraliza-
tion analysis. Neutralizing activities of plasma samples 
from P08 and P11 and neutralizing sensitivity of P08 and 
P11 pseudoviruses to various bnAbs were analyzed as 
previously described [43]. In brief, 100 TCID50 of pseu-
doviruses was incubated with serially diluted plasma, 
or various bnAb in a 96-well plate in triplicate for 1 h at 
37  °C. Approximately 2  ×  104 TZM-bl cells were then 
added and the cultures were maintained for an additional 
48 h at 37 °C. Neutralizing activity was measured by the 
reduction in luciferase activity compared with controls 
(Bright-Glo luciferase assay system, E2650, Promega). 
Half-maximal inhibitory concentrations or dilutions (IC50 
or ID50) were reported as the concentration for bnAbs or 
dilution for plasma required to inhibit infection by 50 % 
compared with the controls. The values were calculated 
using the dose–response inhibition model with a variable 
slope in GraphPad Prism, version 5.0 (GraphPad Soft-
ware Inc., La Jolla, CA, USA). The bnAb PG9 and PG16 
were kindly provided by Wayne Koff at International 
AIDS Vaccine Initiative (IAVI), VRC01 by John Mascola 
of Vaccine Research Center at NIH, 3BNC117 by Michel 
Nussenzweig at Rockefeller University, and Ibalizumab 
by David Ho at Aaron Diamond AIDS Research Center 
of Rockefeller University. The rest of the bnAbs were 
obtained from NIH reference and reagents program.
Generation and verification of envelope chimeras
Chimeric gp160 envelopes were generated using an over-
lapping PCR strategy with gp120, gp41, V3C3V4, V1V2 
subdomains amplified separately and then together 
with the flanking regions from the backbone of CNE6. 
The resultant envelope chimeras were cloned into the 
pcDNA3.1 (Invitrogen), verified by sequencing before 
used for pseudovirus production. Sensitivity of chimeric 
pseudoviruses to plasma neutralization was measured as 
described above.
Construction and expression of transmitted/founder HIV‑1 
envelope combinatorial libraries on the surface of yeast 
Saccharomyces cerevisiae
Construction of yeast library displaying the combinato-
rial antigens was carried out as described previously [34]. 
In brief, the full-length P08 and P11 envelope gene from 
the day 30 and day 18 after infection, respectively, was 
amplified by single molecule PCR, purified (QIAquick 
DNA purification kit, QIAGEN) and digested by DNase 
I into fragments about 50 base pair (bp) in length. The 
digested fragments were reassembled to approximately 
100–600  bp fragments through controlled number of 
PCR cycles, added A-tails (DNA A-tailing kit, TAKARA) 
and ligated to the modified yeast surface displayed vector 
pCTCON2-T. The ligation products were transformed 
into the Escherichia coli competent cells, amplified, 
extracted and then further transformed into the compe-
tent yeast cell line EBY100 using electroporation. Trans-
formed yeast cells were partially spread on SDCAA Amp 
plates and incubated overnight at 30  °C to estimate the 
number and insert sequences of colonies for quality con-
trol purpose. Conditions for yeast growing and induction 
of surface antigen expression in solution have been previ-
ously described [34]. In short, EBY100 yeasts were first 
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grown in SDCAA media at 30 °C for 48 h. At the expo-
nential growth phase, yeasts were transferred to SGCAA 
media for induction of antigen expression at 20  °C for 
48  h before incubating with either plasma samples or 
monoclonal antibodies for subsequent analysis [34].
Immunofluorescence staining, sorting, sequencing 
and sequence analysis of bnAb‑ or plasma‑reactive yeast 
clones by FACS
The entire procedure was conducted as previously 
described [34]. Induced yeast cells (106–107) were col-
lected by centrifugation (6000 rmp/s, 1 min), washed twice 
with cold PBS and incubated with either bnAb or patient 
plasma (1:100 dilution) on ice for 1 h with occasional agi-
tation. After washed three times with cold PBS, the cells 
were incubated with PE labeled anti-human IgG secondary 
antibody (1:200 dilution, rabbit anti-human IgG-PE, Santa 
Cruz) on ice for another 45 min, washed again with PBS 
for three times, analyzed and sorted for positive clones 
using FACS Aria II (BD, USA). The positive yeast clones 
were grown in SDCAA before plasmids were extracted 
(Yeast plasmid kit, Omega Bio-Tek) for sequencing and 
sequence analysis (Sequencher 5.0, Gene Codes Corp.). 
The most frequently recognized amino acid residues 
within each subdomain were calculated as over 90 % per-
centile among the selected fragments for each subdomain.
Measurement of Kd and Ka for each antigenic subdomain
The technique relies on measuring the MFI of the bound 
polyclonal antibodies, at and variety of concentrations 
of polyclonal antibodies, on the c-myc positive yeast 
[56]. Specifically, four representative yeast clones were 
selected from each envelope subdomain based on their 
coverage and mixed in equal proportion (106 cells) before 
incubated with a serial 1:3 dilution of sequential plasma 
samples from P08 and P11. After washed twice with cold 
PBS, the mixture was resuspended in PE labeled anti-
human secondary antibody (1:200 dilution, rabbit anti-
human IgG-PE, Santa Cruz) and incubated for another 
hour. Antibody recognition of yeast clones expressing the 
distinct envelope subdomains were detected by FACS. 
The MFI was recorded, plotted and fitted using a non-
linear least square curve against the reciprocal plasma 
dilution. Kd value was determined using the following 
equation: y = MFImax × Plasmadilution−1/(Kd + Plas-
madilution−1). Ka is the reciprocal of Kd.
Measurement of plasma binding to trimeric 
and monomeric gp120 and gp140 by ELISA
Trimeric ectodomain of NL4-3 (subtype B) constructed 
based on BG505 SOSIP.664 [42] was kindly provided by 
Dr. Yi Shi at Institute of Microbiology, Chinese Academy 
of Sciences. Monomeric gp120 and monomeric gp140 
(CRF01_AE) derived from a CRF01_AE circulating strain 
CM235 (Genebank #: AAG28611) isolated in Thailand in 
year 2000 were purchased and produced from 293T cells 
(Immune Technology Corp, China). Recombinant enve-
lope glycoprotein was coated overnight at 4  °C on the 
96-well plate (100 ng/well), blocked for 2 h at 37  °C with 
1 % bovine serum albumin (BSA) in PBS before addition 
of ten serial threefold dilutions of plasma samples. After 
incubating for 1 h at 37 °C and three-time thorough washes 
with PBST (PBS with 0.05 % Tween), the secondary anti-
body conjugated with horseradish peroxidase (1:4000 dilu-
tion, anti-human IgG-HRP, Promega) was added before 
applying substrate for detectioin. Maximum absorbance at 
450 nm and corresponding plasma dilution were recorded 
(Microplate Reader, Bio-Rad). Plasma samples from HIV-1 
negative individuals were included as negative controls.
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